GLP-1RA Medications Linked to Lower Opioid Overdose Risk

A study found that certain diabetes drugs were associated with reduced overdose hazards among veterans.

Updated on Oct. 6, 2026 in Diabetes

Two empty clear glass medical vials sit on a clean brushed-steel laboratory surface in bright, even lighting. — A study of veterans with type 2 diabetes suggests that semaglutide or tirzepatide may be linked to a lower risk of opioid overdose. AI Illustration. Upload story photo >

Live Poll

Do you trust that weight loss medications can effectively serve as a treatment for opioid addiction?

A study published on October 6, 2026, indicated that patients taking semaglutide or tirzepatide experienced a lower risk of opioid overdose compared to those on insulin or SGLT2 inhibitors. The research tracked veterans diagnosed with type 2 diabetes and opioid use disorder from January 1, 2020, through December 31, 2024.

Why it matters

Researchers investigated whether GLP-1RA use influences opioid overdose outcomes, potentially offering a new strategy for managing comorbid conditions. The findings highlight a potential secondary benefit for patients, though the authors caution that the results are not yet definitive.

The study analyzed 315 patients with a median age of 60. Results showed 8 overdoses in the semaglutide/tirzepatide group compared to 24 in the insulin group, and 5 overdoses versus 19 in the SGLT2 inhibitor group.

The players

Michael J. Crescenz Veterans Affairs Medical Center

This facility served as the site for the primary research affiliation.

Loyola University Chicago

This institution was the affiliation of a peer reviewer for the study.

Stanford University

This university was the affiliation of an expert reviewer for the study.

The details

The analysis compared the overdose hazard ratios for veterans treated with five common diabetes medications. While researchers observed lower overdose rates for those on semaglutide or tirzepatide, they noted no statistically significant difference when compared to patients taking metformin, sulfonylureas, or DPP-4 inhibitors.

January 1, 2020, to December 31, 2024: The period used to track patients diagnosed with T2DM and OUD.
October 6, 2026: The publication date of the research findings.

The Big Picture

This retrospective study provides observational evidence that precedes ongoing randomized clinical trials of semaglutide in patients receiving methadone or buprenorphine. The future results from these trials are expected to provide more definitive data on the efficacy of these treatments.

Patients should consult with their healthcare providers regarding these findings as they are not currently clinical standard-of-care guidelines. Treatment decisions for type 2 diabetes and opioid use disorder should remain based on established medical evidence and individual patient history.

The takeaway

While the findings suggest a potential link between certain diabetes medications and reduced overdose risk, they remain preliminary. Patients should avoid making changes to their medication regimen without direct supervision from a qualified medical professional.

What happens next

Randomized clinical trials testing semaglutide in patients receiving methadone or buprenorphine are currently underway, with results expected in a few years.